# OnCo record orient-32 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/orient-32/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "orient-32", "NCT03794440" ;
  schema:name "ORIENT-32"@en ;
  schema:description "A Chinese trial showing that a PD-1 antibody plus a bevacizumab copy extends life in liver cancer, mirroring the global IMbrave150 result in a hepatitis B population."@en ;
  schema:url <https://onco.cc/trials/orient-32/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03794440>, <https://doi.org/10.1016/S1470-2045(21)00252-7> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "2/3" ;
  schema:startDate "2019-02-11" ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:drugs <https://onco.cc/drugs/sintilimab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/sorafenib/> ;
  onco:companies <https://onco.cc/companies/innovent/> ;
  onco:terms <https://onco.cc/terms/hbv-hcv/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ren-lancet-oncol/> .